Gonadorelin

Gonadorelin (GnRH) and its agonist analogues are used across several clinical conditions, primarily involving hormonal regulation and reproductive health.

Central Precocious Puberty

GnRH agonist therapy is a primary treatment for central precocious puberty in children. Recent systematic reviews indicate that treatment with GnRH agonists can help manage pubertal progression and final height outcomes, though specific efficacy data from the available evidence is limited. The diagnostic utility of basal luteinizing hormone levels is being evaluated as a tool to better identify candidates for GnRH therapy in these cases.

Emerging research suggests that combining gamma-aminobutyric acid (GABA) supplementation with GnRH analog therapy may offer benefits for linear growth in children with growth retardation compared to GnRH therapy alone, though this remains under investigation.

Prostate Cancer Treatment

GnRH agonists are used as part of androgen deprivation therapy (ADT) in prostate cancer care. Clinical trials are actively investigating the optimal use of ADT combined with stereotactic body radiation therapy (SBRT) for unfavorable intermediate-risk prostate cancer. However, cardiovascular health considerations have emerged as an important factor when using long-term androgen deprivation therapy.

Assisted Reproductive Technology

In fertility treatments, GnRH agonists and antagonists play crucial roles in controlled ovarian stimulation protocols. Recent systematic reviews and meta-analyses have compared progestogen-primed ovarian stimulation with GnRH antagonist/agonist protocols for women undergoing assisted reproduction, though specific comparative effectiveness data is not detailed in the available evidence.

Clinical trials are examining the use of GnRH agonists for luteal phase support compared to traditional progesterone/estradiol regimens in IVF/ICSI cycles.

Endometriosis and Adenomyosis

GnRH agonists are used in treating endometriosis and adenomyosis. Research has examined reproductive outcomes following frozen embryo transfer in patients with different adenomyosis subtypes after ultralong GnRH agonist pretreatment, suggesting potential benefits in specific patient populations.

Important Note: This information is for educational purposes only and should not replace professional medical advice. Treatment decisions should always be made in consultation with qualified healthcare providers who can assess individual patient circumstances and medical history.

Note: The available evidence provides limited specific outcome data for many of these applications, and several studies are still ongoing or recently completed.